Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.90 |
| ▸ | CCR5 | P51681 | 12/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575126 | 1.00 | KCNH2 (0.90) | KCNH2CCR5 | |
| SCHEMBL3070604 | 0.95 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL3070606 | 0.95 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL14633678 | 0.94 | CCR5 (0.86) | KCNH2CCR5 | |
| SCHEMBL14633680 | 0.94 | CCR5 (0.86) | KCNH2CCR5 | |
| SCHEMBL1080663 | 0.93 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL1198749 | 0.93 | KCNH2 (1.00) | KCNH2CCR5 | |
| Pf-232798 SCHEMBL1049072 | 0.93 | CCR5 (1.00) | KCNH2CCR5 | |
| SCHEMBL3073059 | 0.93 | KCNH2 (0.88) | KCNH2CCR5 | |
| SCHEMBL3079829 | 0.93 | KCNH2 (1.00) | KCNH2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2741777-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-01-18 | — | — | EP | claimed |
| EP-1937639-B1 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | claimed |
| EP-1492789-B1 | TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2006-06-07 | — | — | EP | claimed |
| EP-2552429-A1 | COMBINATION THERAPY COMPRISING A CCR5 ANTAGONIST, A HIV-1 PROTEASE INHIBITOR AND A PHARMACOKINETIC ENHANCER | Phivco-1 LLC (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-2459216-A2 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | Novartis AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011121558-A1 | COMBINATION THERAPY COMPRISING A CCR5 ANTAGONIST, A HIV-1 PROTEASE INHIBITOR AND A PHARMACOKINETIC ENHANCER | PHIVCO-1 LLC (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20080299132-A1 | Synergistic compositions for treating HIV-1 | ROCHE PALO ALTO LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299132-A1 | Synergistic compositions for treating HIV-1 | CCR5, CD4, HAVCR2 | KCNH2 4770/4885CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.